How to buy Compass Therapeutics (CMPX) stock

Updated Feb 9, 2021

Fact checked

Compass Therapeutics stock is not yet available to purchase on any exchange. But it's expected to go public soon. Here's what we know — and how to buy in when it launches.

What we know about the Compass Therapeutics IPO

Compass Therapeutics filed a draft registration with the US Securities and Exchange Commission under the ticker symbol CMPX. Not yet an official IPO, it's one of the first steps of taking a private company public.

The stock is expected to cost between $5.00 and $6.00. No date has been set for when the stock will be publicly available. The shares will be available on the Nasdaq Capital Market.

Note that Compass Therapeutics is a separate IPO from Compass, a real estate brokerage expected to go public around the same time.

How to buy shares in Compass Therapeutics when it goes public

Once Compass Therapeutics goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Open your brokerage account. Complete an application with your details.
Confirm your payment details. Fund your account.
Research the stock. Find the stock by name or ticker symbol – CMPX – and research it before deciding if it's a good investment for you.
Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.

Our top pick for

Active traders

Tradier

Our top pick for

Beginners

SoFi Invest

Our top pick for

Building a portfolio

JPMorgan Self-Directed Investing

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

Our pick for active traders. We chose Tradier for this because it offers a wealth of tools and data for active traders, including the ability to use its data and create a custom trading platform.
Our pick for beginners. We chose SoFi for this category because it offers commission-free stocks and an easy-to-use mobile app that's highly-rated by customers. SoFi also has financial advisers on staff to help talk you through trading strategies and financial goals — for free. Plus, there's no minimum to open an account.
Our pick for building a portfolio. We chose JPMorgan for this category because offers access to stocks, bonds, mutual funds and ETFs. Chase also offers savings accounts and CDs, and you're able to keep track of all of your Chase accounts, including your JPMorgan investing account, from one hub. This wide selection of investments makes it convenient to build a diverse portfolio with low-, medium-, and high-risk investments.

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. But evaluating the performance of companies like Compass Therapeutics can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Select a company to learn more about what they do and how their stock performs, including market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield. While this list includes a selection of the most well-known and popular stocks, it doesn't include every stock available.

Company summary
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Historical performance
Stock information
- Market capitalization: $207147040
- P/E ratio: 15.3242
- Dividend yield: 0%
Get more detailed information and learn how to buy SURF.US stock
Company summary
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Historical performance
Stock information
- Market capitalization: $346919168
- PEG ratio: 0
- Dividend yield: 0%
Get more detailed information and learn how to buy JNCE.US stock
Company summary
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Historical performance
Stock information
- Market capitalization: $2911785984
- Dividend yield: N/A%
Get more detailed information and learn how to buy RLAY.US stock

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Name	Asset types	Option trade fee	Annual fee	Signup bonus
TradeStation	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract	$0 per month	$10 of crypto Open an account with access to crypto	A platform built for all kinds of traders and all styles of trading	Go to site More Info	loading Fetching your data...
SoFi Invest	Stocks, ETFs, Cryptocurrency	N/A	0%	Get one free stock worth up to $1,000 Open an account	A free way to invest in most equities.	Go to site More Info	loading Fetching your data...
Robinhood	Stocks, Options, ETFs, Cryptocurrency	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info	loading Fetching your data...
Moomoo	Stocks, Options, ETFs	$0	$0 per year	Get a free stock valued up to $3500 Open your Futu brokerage account via Moomoo	Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.	Go to site More Info	loading Fetching your data...
JPMorgan Self-Directed Investing	Stocks, Bonds, Options, Mutual funds, ETFs	$0 + $0.65/contract	0%	$125 - $625 Open and fund an account with $25,000 - $250,000+	INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE	Go to site More Info	loading Fetching your data...

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Thank you for your feedback!

How to buy ImmunoPrecise Antibodies stock How to buy INVO Bioscience stock

More guides on Finder

Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
How to buy HeartCore Enterprises (HTCR) stock when it goes public
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
How to buy Credo Technology Group Holding (CRDO) stock when it goes public
Everything we know about the Credo Technology Group Holding IPO, plus information on how to buy in.
How to buy Hongli Group (HLP) stock when it goes public
Everything we know about the Hongli Group IPO, plus information on how to buy in.

Ask an Expert

Click here to cancel reply.

Display Name

Your Email (will not be published)

Your Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

How to buy Compass Therapeutics (CMPX) stock when it goes public

Here's everything we know so far about the Compass Therapeutics IPO.

What we know about the Compass Therapeutics IPO